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Background
The emerging multidrug resistant (MDR) and extensively
drug resistant (XDR) Mycobacterium tuberculosis (MTB)
infection is increasing with greater complexity, estimated
220000-400000 tuberculosis cases emerged in 2011 glob-
ally. A number of lead compounds have been developed
for treatment of MDR and XDR TB, but no new chemical
entity has emerged for clinical use. Recently DprE1 and
AHAS have been identified as promising drug targets.
Methods
The methodology involved in silico studies, synthesis
and in vitro evaluation for inhibition of M. tuberculosis.
In silico studies involved protein preparation for DprE1,
AHAS, docking and analysis of docking results. Sixty
two substituted (thiazolidine-2-yl amino) benzthiazolyl-
phenylhydrazine carbothiamide derivatives were studied.
In vitro evaluation was carried out by modified agar dif-
fusion method.
Results
About 62 compounds were synthesized based on molecu-
lar docking studies. In case of DprE1 maximum interac-
tions were found with His132, Asn385, Gly133, Leu134,
Leu363, Val365, whereas in case of AHAS maximum
interactions were shown between Arg318, Gly138,
Lys197, Trp516 and Phe147. All compounds were
synthesized in satisfactory yield and structurally eluci-
dated. The range of MIC was found between 40-80 mg/L
with percentage inhibition in range of 80-95%.
Conclusion
Experimental results reveales that newly developed com-
pounds exhibited promising antitubercular activity
which can be further explored for development of
potent drugs.
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